Instituto de Investigación Sanitaria de Navarra-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2023

  1. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  2. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience

    Cancers, Vol. 15, Núm. 3

  3. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2021

  1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  2. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

  3. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  2. Genetic mouse models as in vivo tools for cholangiocarcinoma research

    Cancers, Vol. 11, Núm. 12

  3. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  4. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

    Drug Safety, Vol. 42, Núm. 2, pp. 281-294

  5. Vaccination for pancreatic ductal adenocarcinoma: A hard nut to crack

    Clinical Cancer Research, Vol. 25, Núm. 18, pp. 5435-5437

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Adjuvant therapy for colon cancer: Genes, genes. . . And the patient in the center

    Clinical Cancer Research, Vol. 24, Núm. 16, pp. 3787-3789

  3. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

  4. Revisiting interleukin-12 as a cancer immunotherapy agent

    Clinical Cancer Research, Vol. 24, Núm. 12, pp. 2716-2718

2017

  1. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

    Nature Communications, Vol. 8

  2. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies

    Brachytherapy, Vol. 16, Núm. 6, pp. 1246-1251

2016

  1. Immunotherapy of cancer visualized by live microscopy: Seeing is believing

    Clinical Cancer Research, Vol. 22, Núm. 17, pp. 4277-4279